Bibliography
- Lee WM. Acute liver failure in the United States. Semin Liver Dis 2003;23:217-26
- Holt MP, Ju C. Mechanisms of drug-induced liver injury. AAPS J 2006;8:E48-54
- Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005;4:489-99
- Williams DP. Toxicophores: investigations in drug safety. Toxicology 2006;226:1-11
- Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. Lippincott Williams & Wilkins; Philadelphia, PA: 1999
- Pirmohamed M. Genetic factors in the predisposition to drug induced hypersensitivity reactions. AAPS J 2006;8:E20-6
- Kalgutkar AS, Gardner I, Obach RS, A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab 2005;6:161-225
- Kassahun K, Pearson PG, Tang W, Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem Res Toxicol 2001;14:62-70
- Park BK, Kitteringham NR, Maggs JL, The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol 2005;45:177-202
- Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 2005;35:325-61
- Boelsterli UA, Ho HK, Zhou S, Leow KY. Bioactivation and hepatotoxicity of nitroaromatic drugs. Curr Drug Metab 2006;7:715-27
- Farrell GC. Drug-induced liver disease. Churchill Livingstone; New York: 1994
- Assis DA, Navarro VJ. Human drug hepatotoxicity: a contemporary clinical perspective. Expert Opin Drug Metab Toxicol 2009;5:463-73
- Cheng A, Dixon SL. In silico models for the prediction of dose-dependent human hepatotoxicity. J Comput Aided Mol Des 2003;17:811-23
- Li AP. An integrated, multidisciplinary approach for drug safety assessment. Drug Discov Today 2004;9:687-93
- Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-85
- Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731-9
- Williams DP, Park BK. Idiosyncratic toxicity: the role of toxicophores and bioactivation. Drug Discov Today 2003;15:1044-50
- Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009;16:3041-53
- Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004;38(2):44-8
- Vendemiale G, Grattagliano I, Altomare E, Effect of acetaminophen administration on hepatic glutathione compartmentation and mitochondrial energy metabolism in the rat. Biochem Pharmacol 1996;52:1147-54
- Kaufmann P, Torok M, Hanni A, Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology 2005;41:925-35
- Pessayre D, Mansouri A, Haouzi D, Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 1999;15:367-73
- Waldhauser KM, Torok M, Ha HR, Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives. J Pharmacol Exp Ther 2006;319:1413-23
- Gunawan BK, Liu Z, Han D, N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology 2006;131:165-78
- Henderson NC, Pollock KJ, Frew J, Critical role of c-jun (NH2) terminal kinase in paracetamol- induced acute liver failure. Gut 2007;56:982-90
- Latchoumycandane C, Goh CW, Ong MM, Boelsterli UA. Mitochondrial protection by the JNK inhibitor leflunomide rescues mice from acetaminophen-induced liver injury. Hepatology 2007;45:412-21
- Schwabe RF, Brenner DA. Mechanisms of liver injury. TNFalpha- induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol 2006;290:G583-9
- Orlandini GE, Capaccioli S, Orlandini SZ. Aponecrosis: morphological and biochemical exploration of a syncretic process of cell death sharing apoptosis and necrosis. J Cell Physiol 2000;182:41-9
- Papucci L, Formigli L, Schiavone N, Apoptosis shifts to necrosis via intermediate types of cell death by a mechanism depending on c-myc and bcl-2 expression. Cell Tissue Res 2004;316:197-209
- Farkas D, Tannenbaum S. In vitro methods to study chemically-induced hepatotoxicity: a literature review. Curr Drug Metab 2005;6:111-25
- Dambach DM, Andrews BA, Moulin F. New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol Pathol 2005;33:17-26
- Xu JJ, Henstock PV, Dunn MC, Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 2008;105:97-105
- Balls M. Modern alternative approaches to the problem of drug-induced liver injury. ATLA 2011;39:103-7
- Hultin-Rosenberg L, Jagannathan S, Nilsson KC, Predictive models of hepatotoxicity using gene expression data from primary rat hepatocytes. Xenobiotica 2006;36:1122-39
- Olson H, Betton G, Robinson D, Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000;32:56-67
- Shi Q, Hong W, Senior J, Tong W. Biomarkers for drug-induced liver injury. Expert Rev Gastroenterol Hepatol 2010;4:225-34
- Green RM, Flamm SAG. A technical review on the evaluation of liver chemistry tests. Gastroenterology 2002;123:1367-84
- FDA guidance for industry. Drug-induced liver injury. Premarketing clinical evaluation. Available from: www.fda.gov/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm064993.htm
- Tolman KG. Defining patient risks from expanded preventive therapies. Am J Cardiol 2000;85:15E-9E
- Senior JR. How can “Hy's law” help the clinician? Pharmacoepidemiol Drug Saf 2006;15:235-9
- Ozer J, Ratner M, Shaw M, The current state of serum biomarkers of hepatotoxicity. Toxicology 2008;245:194-205
- Fabris L, Cadamuro M, Okolicsanyi L. The patient presenting with isolated hyperbilirubinemia. Dig Liver Dis 2009;41:375-81
- Watkins PB, Caviness VS. Biomarkers for the diagnosis and management of drug-induced liver injury. Semin Liver Dis 2009;24:393-9
- Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol 2009;62:481-92
- O'Brien PJ, Slaughter MR, Polley SR, Kramer K. Advantages of glutamate dehydrogenase as a blood biomarker of acute hepatic injury in rats. Lab Anim 2002;36:313-21
- Heijne WH, Stierum RH, Leeman WR, van Ommen B. The introduction of toxicogenomics; potential new markers of hepatotoxicity. Cancer Biomark 2005;1:41-57
- Pham BN, Bemuau J, Durand F, Eotaxin expression and eosinophil infiltrate in the liver of patients with drug-induced liver disease. J Hepatol 2001;34:537-47
- Tarantino G, Di Minno MN, Capone D. Drug-induced liver injury. Is it somehow foreseeable? World J Gastroenterol 2009;15:2817-33
- Davern TJ II, James LP, Hinson JA, Acute Liver Failure Study Group. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology 2006;130:687-94
- Blomme EA, Yang Y, Waring JF. Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development. Toxicol Lett 2009;186:22-31
- Pachkoria K, Lucena MI, Molokhia M, Genetic and molecular factors in drug-induced liver injury: a review. Curr Drug Saf 2007;2:97-112
- Natsoulis G, Pearson CI, Gollub JP, The liver pharmacological and xenobiotic gene response repertoire. Mol Syst Biol 2008;4:175
- Clayton TA, Lindon J, Cloarec O, Pharmacometabonomic phenotyping and personalized drug treatment. Nature 2006;440:1073-7
- Bushel PR, Heinloth AN, Li J, Blood gene expression signatures predict exposure levels. Proc Natl Acad Sci USA 2007;104:18211-16
- Valerio LG Jr. In silico toxicology for the pharmaceutical sciences. Toxicol Appl Pharmacol 2009;241:356-70
- Egan WJ, Zlokarnik G, Grootenhuis PDJ. In silico prediction of drug safety: despite progress there is abundant room for improvement. Drug Discov Today 2004;1:381-7
- Greene N, Fisk L, Naven RT, Developing structure-activity relationships for the prediction of hepatotoxicity. Chem Res Toxicol 2010;23:1215-22
- European Commission Research Centre Computational Toxicology Group, Toxtree, version 1.60. Available from: http://ecb.jrc.ec.europa.eu/qsar/qsar-tools/index.php?c=TOXTREE
- Benigni R, Bossa C. Structure alerts for carcinogenicity, and the salmonella assay system: a novel insight through the chemical relational databases technology. Mutat Res 2008;659:248-61
- Patlewicz G, Dimitrov SD, Low LK, TIMES-SS - a promising tool for the assessment of skin sensitization hazard. A characterization with respect to the OECD validation principles for (Q)SARs and an external evaluation for predictivity. Regul Toxicol Pharmacol 2007;48:225-39
- Greene N. Computer systems for the prediction of toxicity: an update. Adv Drug Deliv Rev 2002;54:417-31
- Marchant CA. Virtual ADMET assessment in target selection and maturation. In: Testa B, Turski L, editors. IOS Press; Amsterdam: 2006. p. 237
- Marchant CA, Fisk L, Note RR, An expert system approach to the assessment of hepatotoxic potential. Chem Biodivers 2009;6:2107-14
- Ekins S, Williams AJ, Xu JJ. A predictive ligand-based bayesian model for human drug-induced liver injury. Drug Metab Dispos 2010;38:2302-8
- Cruz-Monteagudo M, Cordeiro MN, Borges F. Computational chemistry approach for the early detection of drug-induced idiosyncratic liver toxicity. J Comput Chem 2008;29:533-49
- Rodgers AD, Zhu H, Fourches D, Modeling liver-related adverse effects of drugs using k-nearest neighbor quantitative structure-activity relationship method. Chem Res Toxicol 2010;23:724-32
- Low Y, Uehara T, Minowa Y, Predicting drug-induced hepatotoxicity using qsar and toxicogenomics approaches. Chem Res Toxicol 2011;24:1251-62
- Matthews EJ, Ursem CJ, Kruhlak NL, Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: part B. Use of (Q)SAR systems for early detection of druginduced hepatobiliary and urinary tract toxicities. Regul Toxicol Pharmacol 2009;54:23-42
- Perkins R, Fang H, Tong W, Welsh WJ. Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology. Environ Toxicol Chem 2003;22:1666-79
- Golbraikh A, Tropsha A. Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection. J Comput Aided Mol Des 2002;16:357-69
- Williams A, Tkachenko V, Lipinski C, Free online resources enabling crowd-sourced drug discovery. Drug Discov World 2010;10:33-9
- PubChem. Available from: http://pubchem.ncbi.nlm.nih.gov
- Chemspider RSC. Available from: http://www.chemspider.com
- ToxNet. Available from: http://toxnet.nlm.nih.gov
- Available from: http://actor.epa.gov/actor/faces/ToxCastDB/Home.jsp
- Available from: http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm106561.pdf
- Cronin MTD. Finding the data to develop and evaluate (Q)SARs and populate categories for toxicity prediction. In: Cronin MTD, Madden JC, editors. In silico toxicology: principles and applications. RSC; Cambridge, UK: 2010:31-58
- Available from: http://www.sunsetmolecular.com
- Available from: http://accelrys.com/products/databases/bioactivity/rtecs.html
- Available from: http://www.cerep.fr
- Available from: https://www.lhasalimited.org/
- Available from: http://www.leadscope.com/
- Available from: https://www.ebi.ac.uk/chembl/
- Fourches D, Barnes JC, Day NC, Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chem Res Toxicol 2010;23:171-83
- Sakuratani Y, Sato S, Nishikawa S, Category analysis of the substituted anilines studied in a 28-day repeat-dose toxicity test conducted on rats: Correlation between toxicity and chemical structure. SAR QSAR Environ Res 2008;19:681-96
- Clark RD, Wolohan PR, Hodgkin EE, Modelling in vitro hepatotoxicity using molecular interaction fields and SIMCA. J Mol Graph Model 2004;22:487-97
- Chan K, Jensen NS, Silber PM, O'Brien PJ. Structure–activity relationships for halobenzene induced cytotoxicity in rat and human hepatoctyes. Chem Biol Interact 2007;165:165-74
- ICH E2D guideline. Post-approval safety data management: definitions and standards for expedited reporting, November 2003. Available from: http://www.ich.org/LOB/media/MEDIA631.pdf
- Ursem CJ, Kruhlak NL, Contrera JF, Identification of structure activity relationships for adverse effects of pharmaceuticals in humans. Part A: use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities. Regul Toxicol Pharmacol 2009;54:1-22
- Ahmad SR. Adverse drug event monitoring at the food and drug administration. Your report can make a difference. J Gen Intern Med 2003;18:57-60
- Gross R, Strom BL. Toward improved adverse event/suspected adverse drug reaction reporting. Pharmacoepidemiol Drug Saf 2003;12:89-91
- Petronijevic M, Ilic K, Suzuki A. Drug induced hepatotoxicity: data from the Serbian pharmacovigilance database. Pharmacoepidemiol Drug Saf 2011;20:416-23
- Cheng A. In silico prediction of hepatotoxicity. Curr Comput Aided Drug Des 2009;5:122-7
- Suter W. Predictive value of in vitro safety studies. Curr Opin Chem Biol 2006;10:362-6
- Todeschini R. DRAGON for windows (Software for Molecular Descriptor Calculations), version 5.4. Talete s. r. l.; Milan, Italy: 2006
- Olson H, Betton G, Stritar J, Robinson D. The predictivity of the toxicity of pharmaceuticals in humans from animal data. An interim assessment. Toxicol Lett 1998;102-03:535-8
- Breiman L, Friedman JH, Olshen RA, Ston CJ. Classification and regression trees. Wadsworth International Group; Belmont, CA: 1984
- Hawkins DM, Kass GV. Topics in applied multivariate analysis. In: Hawkins DH, editor. Cambridge University Press; Cambridge, UK: 1982. p. 269-302
- Dixon SL, Villar HO. Investigation of classification methods for the prediction of activity in diverse chemical libraries. J Comput Aided Mol Des 1999;13:533-45
- Hewitt M, Ellison CM, Enoch SJ, Integrating (Q)SAR models, expert systems and read-across approaches for the prediction of developmental toxicity. Reprod Toxicol 2010;30:147-60
- Li AP. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the “multiple determinant hypothesis” for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact 2002;142:7-23
- Matthews EJ, Kruhlak NL, Benz RD, Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: part C. Use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities. Regul Toxicol Pharmacol 2009;54:43-65
- Tropsha A, Golbraikh A. Predictive QSAR modelling workflow, model applicability domains, and virtual screening. Curr Pharm Des 2007;13:3494-504
- Uehara T, Ono A, Maruyama T, The Japanese toxicogenomics project: application of toxicogenomics. Mol Nutr Food Res 2010;54:218-27
- Cronin MTD. In silico tools for toxicity prediction. In: Wilson AGE, editor. New horizons in predictive toxicology: current status and applications. RSC: Cambridge, UK: 2012:9-25
- Judson PN, Marchant CA, Vessey JD. Using argumentation for absolute reasoning about the potential toxicity of chemicals. J Chem Inf Comput Sci 2003;43:1364-70
- Ellison CM, Madden JC, Judson P, Cronin MTD. Using in silico tools in a weight of evidence approach to aid toxicological assessment. Mol Inform 2010;29:97-110
- Available from: http://www.fda.gov/cder/livertox
- Available from: http://www.epa.gov/ncct/virtual_liver/
- Fontana RJ, Watkin PB, Bonkovsky HL, DILIN Study Group. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009;32:55-68
- Available from: https://www.dilin.dcri.duke.edu/
- Available from: http://www.thehamner.org/dili-sim/
- Available from: http://www.virtual-liver.de/
- Available from: http://www.etoxproject.eu/
- Available from: http://www.imi-safe-t.eu/
- Available from: http://www.cosmostox.eu/
- Richarz AN, Cronin MTD, Neagu DC, COSMOS – a new European project to develop computational models for the repeat dose toxicity of cosmetic ingredients. Altex 2011;28(Special Issue):39-40
- Schultz TW. Adverse outcome pathways: a way of linking chemical structure to in vivo toxicological hazards. In: Cronin MTD, Madden JC, editors. In silico toxicology: principles and applications. RSC; Cambridge, UK: 2010:346-71
- Ankley GT, Bennett RS, Erickson RJ, Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem 2010;29:730-41
- Enoch SJ, Ellison CM, Schultz TW, Cronin MTD. A review of the electrophilic reaction chemistry involved in covalent protein binding relevant to toxicity. Crit Rev Toxicol 2011;4:783-802
- Ellison CM, Sherhod R, Cronin MTD, Assessment of methods to define the applicability domain of structural alert models. J Chem Inf Model 2011;51:975-85
- Ellison CM, Enoch SJ, Cronin MTD. Review of in silico approaches to predict chemistry related drug toxicities. Expert Opin Drug Metab Toxicol 2011;7:1481-95